Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib and Sintilimab with Radiotherapy in Advanced Solid Tumors
NCT05527821Phase 2Unknown
- Start
- Sep 2022
- Primary completion
- Sep 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib in solid tumor (advanced stage), biliary tract cancer (BTC), gastric cancer (GC) and 1 more. Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
surufatinib
03
Conditions
solid tumor (advanced stage)biliary tract cancer (BTC)gastric cancer (GC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05527821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05527821.